Inclusion Criteria:

- 4.1.1 Male or female patients 18 years of age or older 4.1.2 A diagnosis of
refractory or relapsed acute myeloid leukemia, or Ph+ CML, in chronic, accelerated or
blast phase, or acute lymphoblastic leukemia, or myelodysplastic syndrome.

One of the following parameters is required to meet criteria for accelerated phase CML:

- Blasts in Peripheral Blood or Bone Marrow ≥15%

- Promyelocytes and Blasts in Peripheral Blood or Bone Marrow ≥30%

- PB or BM basophils ≥20%

- Thrombocytopenia <100 x 103/ml, not resulting from therapy

Blast phase is defined as ≥30% blasts in peripheral blood or bone marrow, or presence of
extramedullary disease, except for liver or spleen.

4.1.2.1 Patients with CML must have demonstrated resistance and/or intolerance to therapy
with at least 2 tyrosine kinase inhibitors (TKI) 4.1.2.2 AML and Ph+ ALL should have
received at least one prior treatment regimen and either failed to achieve response or
relapsed on treatment.

4.1.2.3 MDS patients should have failed prior therapy with a hypomethylating agent or, if
associated with a 5q- chromosomal abnormality, lenalidomide. Patients with 5q- unable to
receive or intolerant to lenalidomide are also eligible.

4.1.3 Patients must have clinically adequate hepatic and renal functions as defined by:

ALT<2x ULN Serum creatinine concentration <2x ULN Serum bilirubin <2x ULN 4.1.4 Patients
must sign an informed consent. 4.1.5 Women of childbearing age must have a negative serum
or urine pregnancy test prior to the initiation of study drug.

4.1.6 Barrier contraceptive precautions are to be used throughout the trial by all study
participants of child bearing potential.

4.1.7 Patients must be off anti-cancer therapy for at least two weeks prior to study
entry, with the exception of hydroxyurea or anagrelide (24 hours), TKI (5 days), and
interferon (two weeks).

4.1.8 Patients with ECOG Performance of 0-2

Exclusion Criteria:

4.2.1 Serious intercurrent medical illnesses, which would interfere with the ability of
the patient to carry out the treatment program.

4.2.2 Pregnant or breastfeeding women 4.2.3 Patients who have uncontrolled active
infection 4.2.4 Patients who have received another Investigational product within the
longer of 14 days or 5 half-lives of the previous product.

-